[Federal Register Volume 75, Number 136 (Friday, July 16, 2010)]
[Notices]
[Page 41501]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-17430]
[[Page 41501]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
A Transgenic Model of Human Basal Triple Negative Breast Cancer [C3(l)-
tag mice]
Description of Invention: Basal triple-negative breast cancer
(TNBC) is a common form of human breast cancer for which there are no
specific, targeted therapies, unlike hormone-responsive or Her2+ breast
cancers. TNBC has a much worse prognosis than hormone receptor + cancer
and is disproportionately high in the African-American population. NIH
scientists have created and characterized a transgenic model that is
currently an excellent mouse model for TNBC that shares important
molecular characteristics of human TNBC, making it highly useful for
preclinical testing of drugs and novel therapies. This model may
provide a valuable means of identifying new drugs and therapies that
could be translated to human clinical trials. The mouse model also
develops prostate intraepithelial neoplasia and prostate cancer,
therefore has also been used for studies of prostate cancer. The
studies using the mouse model may fill important public health service
needs.
Inventor: Jeffrey E. Green (NCI).
Patent Status: HHS Reference No. E-191-2010/0--Research Tool.
Patent protection is not being pursued for this technology.
Licensing Status: Available for licensing under a Biological
Materials License Agreement.
Licensing Contact: Betty Tong, Ph.D.; 301-594-6565;
[email protected].
Collaborative Research Opportunity: The Transgenic Oncogenesis and
Genomics Section of the Laboratory of Cancer Biology and Genetics,
Center for Cancer Research, is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize this mouse model of TNBC to study
cancer biology and for preclinical testing. Please contact John Hewes,
Ph.D. at 301-435-3121 or [email protected] for more information.
Improved Pepper Spray for Repellency and Incapacitation
Description of Invention: Non-lethal means of temporarily
incapacitating a person are greatly needed for law enforcement and for
personal protection. A common approach is to use pepper spray. Although
current pepper sprays are effective, they cause pain for excessively
long periods, and could be life threatening for people who suffer from
asthma and have hypersensitive airways. This technology describes a
composition for use in an aerosol or spray, that when administered,
causes a painful stimulation and incapacitates a person for only a
brief period. This technology may improve safety over currently
available pepper sprays.
Application: Incapacitating pepper spray with reduced toxicity.
Development Status: Early stage.
Inventors: Peter M. Blumberg and Larry V. Pearce (NCI).
Patent Status: U.S. Provisional Application No. 61/340,063 filed 12
Mar 2010 (HHS Reference No. E-048-2010/0-US-01).
Licensing Status: Available for licensing.
Licensing Contact: Charlene Sydnor, Ph.D.; 301-435-4689;
[email protected].
Dated: July 12, 2010.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2010-17430 Filed 7-15-10; 8:45 am]
BILLING CODE 4140-01-P